Dr. Reddy’s Laboratories has informed that the company (‘Dr. Reddy’s’) has on April 29, 2026, received a Notice of Compliance (i.e. an approval) from the Pharmaceutical Drugs Directorate, Canada (‘Health Canada’) regarding its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. The relevant details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed. A press release being issued in relation to the above matter is also enclosed.
The above information is a part of company’s filings submitted to BSE.
